Living with CML and diabetes - Chronic myeloid leukemia

                  
ARTICLES

How Intermittent Fasting Affects Patients Receiving Tyrosine Kinase Inhibitors for CML
May 25, 2021, Cancer Therapy Advisor

Leukemia Survival Likely Not Affected by Diabetes, Hemoglobin A1C
January 21, 2021, AJMC

Insulin: too much of a good thing is bad
August 21, 2020, BMC Medicine

Korean Study Identifies Benefits of Combining Metformin With Nilotinib in CML
June 2, 2020, JNCCN360

IN VITRO INVESTIGATION OF THE IMPACT OF BCR-ABL TYROSINE KINASE INHIBITORS ON ENDOTHELIAL CELLS
June 2020, EHA 2020

ENDOCRINE EFFECTS INDUCED BY TYROSINE KINASE INHIBITORS DURING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
June 2020, EHA 2020

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes
May 1, 2020, Cell Metabolism

Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase
November 26, 2019, Nature.com

Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor
November 3, 2018, BMC Endocrine Desorders

Genetic Risk of Prediabetes and Diabetes Development in Chronic Myeloid Leukemia Patients Treated With Nilotinib
July 27, 2018, PubMed

Nilotinib Associated With Treatment-induced T2DM and Hyperlipidemia
March 31, 2017, Cancer Therapy Advisor

Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue (bosutinib – quinoline)
March 8, 2017, Nature

Incidence of type II diabetes mellitus among patients with chronic myelogenous leukemia (CML) receiving first or second line therapy with dasatinib or nilotinib
June 2016, ASCO 2016

PPARγ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue
April 2016, American Diabetes Association

Scientists Find Accidental Cure for Type 2 Diabetes: Imatinib
March 29, 2016, AJMC.com Managed Markets Network

Insulin Sensitivity Improved With PPARy Antagonist Imatinib
January 13, 2016, MPR

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia
October 2013, Haematologica

Rapid Amelioration of Hyperglycemia Facilitated by Dasatinib in a Chronic Myeloid Leukemia Patient with type 2 Diabetes Mellitus
2012, Internal medicine – j-Stage - Japan

Diabetes Impairs Hematopoietic Stem Cell Mobilization by Altering Niche Function
October 11, 2011, Bone Marrow Transplantation

Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
November  9, 2009, PublMed

Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL–Positive Cells
May 2009, Clinical Cancer Research

Gleevec Helps Fight Diabetes
March 1, 2009, Korea Times

Two cancer drugs prevent, reverse type 1 diabetes, UCSF study shows
November 17, 2008 , UCSF

Amelioration of diabetes by imatinib mesylate (Gleevec®): role of β-cell NF-κB activation and anti-apoptotic preconditioning
February 2007 , The Faseb Journal
​
Imatinib and Hyperlipidemia
December 22, 2005, The New England Journal of Medicine

Imatinib and Regression of Type 2 Diabetes
March 10, 2005, The New England Journal of Medicine

Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to Treatment
2004, American Society of Clinical Oncology       

          See also     Could fasting cure chronic myeloid leukemia
          See also     Combination of pioglitazone with tyrosine kinase inhibitor
              See also     CML and Nutrition
              See also     CML and comorbidities

​